AspenBio Pharma to Provide Third Quarter 2012 Business Update
Conference Call and Webcast scheduled for November 13, 2012, 4:30 p.m. ET
CASTLE ROCK, Colo., Nov. 5, 2012
CASTLE ROCK, Colo., Nov.5, 2012 /PRNewswire/ --AspenBio Pharma, Inc.
(Nasdaq: APPY), an in vitro diagnostic company, today announced it will
provide a third quarter business update on Tuesday, November 13, 2012, at 4:30
p.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive
Officer; Jeff McGonegal, Chief Financial Officer; and Don Hurd, Senior Vice
President and Chief Commercial Officer.
Interested participants and investors may access the conference call by
dialing 1-800-860-2442 (U.S.), 1-866-605-3852 (Canada) or 1-412-858-4600
(international). A live audio webcast will be accessible via the Investor
Relations section of the AspenBio web site, www.aspenbiopharma.com.
A telephonic replay of the call will be available for two weeks beginning at
8:00 p.m. ET on November 13, 2012. Access numbers for this replay are
1-877-344-7529 (U.S./Canada) and 1-412-317-0088 (international); conference
ID: 10020579. The webcast replay will remain available in the Investors
Relations section of the AspenBio web site for 30 days.
About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the
clinical development and commercialization of its blood-based appendicitis
test. The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. The test is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging. For more information, visit
This press release includes "forward-looking statements" of AspenBio Pharma,
Inc. ("AspenBio") as defined by the Securities and Exchange Commission
("SEC"). All statements, other than statements of historical fact, included in
this press release that address activities, events or developments that
AspenBio believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain assumptions
made based on experience, expected future developments and other factors
AspenBio believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of AspenBio. Investors are cautioned that any such
statements are not guarantees of future performance. Actual results or
developments may differ materially from those projected in the forward-looking
statements as a result of many factors, including our ability to successfully
complete required product development and modifications in a timely and cost
effective manner, complete clinical trial activities for AppyScore required
for FDA submission, obtain FDA clearance or approval, complete and obtain CE
Mark, cost effectively manufacture and generate revenues from AppyScore,
execute agreements required to successfully advance the company's objectives,
retain the management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and enforce
intellectual property rights, and realize value of intangible assets.
Furthermore, AspenBio does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
AspenBio's recent filings with the SEC, including its Final Prospectus filed
on June 20, 2012.
For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
SOURCE AspenBio Pharma, Inc.
Press spacebar to pause and continue. Press esc to stop.